Please Wait
Applying Filters...
Menu
Xls

Digital Content read-more

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2026/01/29/3228188/0/en/OSE-Immunotherapeutics-Selects-Chronic-Pouchitis-and-Hidradenitis-Suppurativa-as-New-Key-Indications-for-Lusvertikimab.html

GLOBENEWSWIRE
29 Jan 2026